Inhibitor-resistant HCV NS3 protease

Details Inhibitor-resistant HCV NS3 protease Inhibitor-resistant HCV NS3 protease

2007-04-24

2007-04-24

Nashed, Nashaat T. (Department: 1656)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Hydrolase

C435S023000, C435S069100, C435S252300, C435S320100, C435S471000

Reexamination Certificate

active

10695140

ABSTRACT:
An inhibitor-resistant HCV NS3 protease is provided which is useful to screen for compounds having therapeutic value against drug resistant HCV strains. In particular, the inhibitor-resistant HCV NS3 protease comprises an amino acid sequence which is mutated in the substrate binding pocket thereof rendering the protease resistant to inhibitor. In a specific aspect of the present invention, at least one of the amino acids at position 155, 156 and 168 of the HCV NS3 protease is mutated to yield an inhibitor-resistant protease.

REFERENCES:
patent: 5843752 (1998-12-01), Dasmahapatra et al.
patent: 5990276 (1999-11-01), Zhang et al.
patent: 6197536 (2001-03-01), Steinkuehler et al.
patent: 6326137 (2001-12-01), Hong et al.
patent: 6608027 (2003-08-01), Tsantrizos et al.
patent: 6706874 (2004-03-01), Kukolj et al.
patent: 6986892 (2006-01-01), Coit et al.
patent: 2005/0074465 (2005-04-01), Houghton
patent: 2005/0136400 (2005-06-01), Lin et al.
patent: WO 00/59929 (2000-10-01), None
patent: WO 02/052015 (2002-07-01), None
patent: WO 200268933 (2002-09-01), None
Yamada et al., 1998, “Critical poin mutations for hepatitis C virus NS3 proteinase”, Virology, vol. 246, No. 1, pp. 104-112.
Llinas-Brunet et al., 1998, “Studies on the C-terminal hexapeptide inhibitors of the hepatitis C virus serine protease”, Bioorganic & Medicinal Chemistry Letters, vol. 8, No. 19, pp. 2719-2724.
Beyer et al., 2001, “Effect of naturally-occurring active site mutations on hepatitis C virus NS3 protease specificity”, PROTEINS: Structure, Function, and Genetics, vol. 43, No. 2, pp. 82-88.
Caterina Trozzi et al; In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor; Journal of Virology Mar. 2003 vol. 7 No. 6 pp. 3669-3679; American Society for Microbiology.
A. Lahm et al; Hepatitis C Virus Proteins as Targets for Drug Development: The Role of Bioinformatics and Modelling; Current Drug Targets (2002) vol. 3 pp. 281-296; Bentham Science Publishers Ltd.
Jan Oliver Koch et al; Determinants of Substrate Specificity in the NS3 Scrine Proteinase of the Hepatitis C Virus; Virology (1997) vol. 237 pp. 78-88; Academic Press.
Annarita Casbarra et al; The effect of prome-site occupancy on the hepatitis C virus NS3 protease structure; Protein Science (2002) vol. 11 pp. 2102-2112; Cold Springs Harbor Laboratory Press.
International Serach Report Reference No. PCT/CA 03/01636.

Affiliated with

Also associated with

Rating

Inhibitor-resistant HCV NS3 protease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitor-resistant HCV NS3 protease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitor-resistant HCV NS3 protease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3755107